1st Quarter Financial Results for FYE/Mar Terumo Corporation July 30, 2009

Transcription

1 1st Quarter Financial Results for FYE/Mar 2010 Terumo Corporation July 30,

2 Financial Results (Unit: Billion yen) Q1 FYE/Mar Q1 FYE/Mar Rate of change Net Sales % Gross profit 42.2(54.3%) 41.6(53.6%) -2% SG&A Expenses 26.0(33.4%) 25.1(32.3%) -4% Operating Income 16.2(20.9%) 16.5(21.3%) 1% Ordinary Income 18.9(24.2%) 16.9(21.9%) -10% Net Income 14.0(18.0%) 10.8(14.0%) -23% Average exchange rate 1US$ 105 yen 97 yen 1EUR 163 yen 133 yen Impact on Net Sales -7% 2

3 Sales (by Region ) +7 % Japan/Outside of Japan Total 0 % (+ 7%) Outside of Japan Total -8 % ( + 7 %) Ratio of outside of Japan 49 % 45 % (Unit: Billion yen) Mar Q1 Mar Q1 ( ) : local currency basis % -2 % -5 % ( + 5%) ( + 6%) (+ 11%) Japan Europe Americas Asia and Others 3

4 Sales ( by Product Group) (Unit: Billion yen) -1% ( + 2%) + 1 % ( + 12%) Mar Q1 Mar Q1 ( ) : local currency basis % ( 0 %) + 54 % ( + 58%) General Hospital Cardiac & Vascular Blood Transfusion Consumer Health-care 4

5 Gross Profit (%) Cost Cut and Others Shift to Highly Profitable Products Price Down Impact of Currency pt FYE/Mar Q1:54.3% FYE/Mar Q1 :53.6% 5

6 SG&A Expenses (Unit: Billion yen) SG&A. expense ratio to sales improved by 1.1pt Japan: -R&D was reinforced 33.4 % 32.3 % -A growth of retirement benefit expense was offset by a reduction of expense Outside of Japan: -Reduced across the Group, and improved due to a favorable impact of foreign exchange Mar Q1 Mar Q1 6

7 Forecast : Forecast for the 1st Half Revised Upward FYE/Mar Q1 Results FYE/Mar st Half Year Forecast (Billion yen) FYE/Mar.2010 Forecast Net Sales Operating Income 16.5(21.3%) 28.0(18.2%) 56.0(17.8%) Ordinary Income 16.9(21.9%) 28.0(18.2%) 56.0(17.8%) Net Income 10.8(14.0%) 18.0(11.7%) 37.5(11.9%) Average exchange rate 1US$ 97 yen Q2 90 yen 95 yen 1EUR 133 yen Q2 120 yen 125 yen 7

8 Topics Performance trend update Growth potential of interventional systems business Others 8

9 Performance Trends Impact Limited Despite Slow Sales of Large Equipment Overseas sales of large-sized equipment for cardiac surgery (billion yen) Large-sized equipment for cardiac surgery: 0 Q1 FYE Mar Q1 FYE Mar Heart-lung machine Sarns Advanced Perfusion System 1 9

10 Performance Trends Big Buyer China Robust Among Emerging Markets (US$ Mil.) China Latin America Eastern Europe / Russia 0 Q1 FYE Mar Q1 FYE Mar

11 Interventional Systems Business Unique Growth Potential Driving Entire Business Expansion New Field Coils for neuro vascularl aneurysm treatment 3 Basic Items (requisites for interventional procedure) Guide wires Introducer kits Angiographic catheter High-Value-Added Medical Devices PTCA balloon catheters Stents Drug-eluting stents, etc billion yen 1985 FYE Mar (Forecast) (conceptual image) 11

12 3 Basic Items That Always Grow Competitive quality that induces demand shifts to Terumo products Growth on market expansion Growth on field diversification Heart High-value-added medical devices Neuro Peripheral 3 basic items 12

13 Extending Portfolio of Guide Wire Products Global brand of Radifocus Guidewire PTCA guide wires Neuro-vascular micro wires Peripheral-vessels guide wires Further into new fields 13

14 Sales Growing on Products Offering Healthcare Economy Benefit PTCA balloon catheter product lineup and sales volume (Japan) No. of units (Thousand) Number used per case 130 (Based on surveys by Terumo) : New products that emphasize healthcare economy benefit Hiryu Tazuna Launched in July 50 Kongo Ryujin Plus 10 03/03 05/03 08/03 10/03 (Forecast) 14

15 New Field Becoming New Growth Pillar Sales of coils for use in treating neuro aneurysms CAGR 29% 8.4 billion yen Acquisition of MicroVention, Inc. 3.0 billion yen FYE Mar FYE Mar (Forecast) 15

16 Coil Market Set to Continue Expanding No. of cases worldwide (Thousand) 100 Trends in the neuro aneurysm treatment market Coil treatment Surgery (clips) 0 (Based on surveys by Terumo)

17 Pursuing Synergies Since The Acquisition Trend in neuro aneurysm treatment [Treatment coils] MicroVention technology [Access devices] Terumo technology + Barecoil Hydrocoil HydroSoft 3 basic items Micro wire Guiding catheter Coils for abdominal peripheral arteries 17

18 Other Topics 1) U.S. (U.S.$ Mil.) 200 Sales recording continuous growth since the start of direct sales CAGR 14% % Start of direct sales 0 FYE Mar FYE Mar (Sales of catheter products in the U.S. market) FYE Mar FYE Mar FYE Mar (Forecast) 18

19 Other Topics 2) Thailand Leveraging the Terumo brand to offer a full lineup of products # Hospitals: pursuing a safety strategy # Entry into the diabetes treatment business # The no.1 presence in interventional systems (Terumo share:40% Exclude DES) CAGR 24% Blood Transfusion 11% Consumer Health-care 1% (U.S.$ Mil.) 23 FYE Mar FYE Mar Cardiac & Vascular 27% General Hospital 61% 19

20 Summary # The strong yen has been a big problem, but we are gradually overcoming it. # We have had some success in boosting our profitability. # We have made a smooth start in achieving our goal of increasing revenues and profits. 20

21 Reference 21

22 Factor of Change of Sales and Operating Profit [Sales] Q1 Mar.2009: 77.8 bln yen Q1 Mar. 2010: 77.5 bln yen bln yen Increase of amount Impact of currency Price down [Operating Income] Q1 Mar.2010: 16.2 bln yen Q1 Mar. 2010: 16.5 bln yen Increase of amount / Improving product mix line and others Impact of currency Price down +3 bln yen SG&A expense increase -7 22

23 Reference (Unit: millions of yen) Mar st Quarter Mar st Quarter Mar Forecast R&D Expense 3,772 3,922 19,000 Depreciation Expense 4,641 4,481 21,000 Investment in Plant and Equipment Free Cash Flow 3,235 5,157 23,000-10, Shareholder's Equity Per Share (Yen)

24 Tazuna, New PTCA Balloon Catheter Suitable for TRI Launched Requisites for penetration of TRI procedures * What s TRI In TRI (Transradial Coronary Intervention), a balloon catheter is inserted from a micro wrist artery to approach the coronary artery. It imposes as little physical burden on patients as they can walk soon after the operation, and facilitates outpatient surgery. Device Development To minimize in diameter and improve in smooth accessibility Safety to be reduced (less bleeding) Medical Education Trainig Benefits to Hospitals Low cost and easy to take care of patients Need of Patients Early post-surgery recovery 24

25 IR Contact TERUMO Corporation Corporate Communication (IR) Dept. Among the information that Terumo discloses, forecasts of financial performance on future projections contain potential risks and uncertainty since these are forecasts on projections made by Terumo based on limited information available at the moment of disclosure. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition. The market share information in this booklet is partly derived from our own independent research. 25